GoodRx
Valuation each multiple against its own 5-year range
Vs. peers Health Information Services
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| GoodRx (GDRX) | 996.14M | 48.67 | 1.54 | 0.00% |
| Veeva Systems (VEEV) | 43.10B | 43.64 | 5.80 | 0.00% |
| BrightSpring Health Services (BTSG) | 12.50B | 33.78 | 5.75 | 0.00% |
| Tempus AI (TEM) | 9.86B | -50.98 | 19.70 | 0.00% |
| Hinge Health (HNGE) | 8.60B | 51.68 | 28.71 | 0.00% |
| HealthEquity (HQY) | 7.84B | 34.21 | 3.94 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 66.7% below Morningstar's fair value estimate.
Fair value
GoodRx Holdings Inc is assigned a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 27% discount to our quantitative fair value estimate of $4.87 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's profitability increases our estimated valuation. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 8.8%, which lies in the top 30% globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are undervalued.
The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 5.7, a core component of valuation, falls in the bottom 20% compared with global peers. Relative to the company's EBITDA, the enterprise value of the business is low, which further promotes our favorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:50:20 · For reference only, not investment advice and not tailored to your situation.
GoodRx discussion 0 comments